A multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 microg administered either in a once-daily in the morning regimen (160 microg qd AM) for 16 weeks or in a 160 microg qd AM regimen for 12 weeks preceded by a twice-daily regimen (80 microg bid) for 4 weeks, or in an 80 microg bid regimen for 16 weeks, in adults and adolescents with mild to moderate persistent asthma not treated with steroids.

Trial Profile

A multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 microg administered either in a once-daily in the morning regimen (160 microg qd AM) for 16 weeks or in a 160 microg qd AM regimen for 12 weeks preceded by a twice-daily regimen (80 microg bid) for 4 weeks, or in an 80 microg bid regimen for 16 weeks, in adults and adolescents with mild to moderate persistent asthma not treated with steroids.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Ciclesonide (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 20 May 2009 Results reported at the 105th International Conference of the American Thoracic Society.
    • 22 Dec 2008 Actual patient number (708) added as reported by ClinicalTrials.gov.
    • 20 Apr 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top